Content intended for healthcare professionals. By continuing, you confirm you are a HCP.
TBS Contract research services
CRO services: Bone-quality endpoints for your clinical trials
Partner with the team behind the global standard in bone microarchitecture. We bring validated TBS® analysis and central DXA reading to studies where bone is an efficacy or safety signal.
Why partner with us
A sensitive, validated bone endpoint — and the team that built it
Bone is increasingly a factor in trials far beyond osteoporosis: Oncology therapies, anti-diabetics, glucocorticoids and endocrine agents can all move bone quality before they move bone density. Trabecular Bone Score® (TBS®) captures that structural change, often earlier and more sensitively than BMD alone.
As the developer of TBS®, Medimaps offers sponsors a rare combination: A regulatory-grade analytical method, centralised image handling, and direct access to the scientific team whose work is cited across international guidelines.
35+
guidelines reference TBS®1
1,600+
peer-reviewed TBS® publications1
45
M
TBS® evaluations performed annually1
90+
countries with clinical deployments1
Ready for multi-region trials. MDSAP certification means our quality system has already passed a single audit recognised by five regulators: FDA, Health Canada, TGA, ANVISA and PMDA.
What we offer
End-to-end bone assessment for your study
From protocol design through to a clean, analysis-ready dataset.
Central TBS & DXA analysis
Standardised, blinded central reading across all your sites, removing inter-site variability from your bone data
Bone-quality endpoints
TBS® as a primary, secondary or safety endpoint, capturing microarchitectural change BMD can miss
Study design support
Protocol and statistical input on where and how bone-quality measures strengthen your evidence
Regulatory-grade data
Documentation and QC aligned to an ISO 13485 quality system, ready for submission scrutiny
Scientific advisory
Direct access to the research team behind TBS® for scientific rationale, publications and expert input
Analysis & reporting
Clean, analysis-ready datasets and clear reporting, delivered to your biostatistics team on schedule
The scientific case
Why bone quality belongs in your protocol
- Detects change earlier: Microarchitectural decline can precede measurable density loss — a more responsive signal over a trial's timeline
- Independent of BMD: TBS® adds information density doesn't capture, strengthening the completeness of your bone-safety story
- From existing scans: Derived from standard lumbar-spine DXA; no additional imaging modality or patient burden to add to your protocol
Same scan
TBS® is computed from the very DXA image already acquired for BMD — a second, structural endpoint at no added patient dose.
Applicable across therapeutic areas where bone is an efficacy or safety consideration: Oncology, Endocrinology, Diabetes, Rheumatology, women's health, and more.
TBS · Trabecular Bone Score
The global standard in bone microarchitecture assessment
TBS® is a patented, validated analytical index derived from routine DXA scans, revealing the internal structural quality of bone that BMD cannot measure. More than a decade of peer-reviewed research underpins its clinical use worldwide.
Clinically proven
TBS evidence keeps growing
2026 · Diagnostics
Razvan, D.V., Rosca, O., et al.
2024 · The Journal of Clinical Endocrinology and Metabolism
Bioletto, F., Barale, M., et al.
2023 · Osteoporosis International
Hans, D., McDermott, M., et al.
How it works
A straightforward engagement
1
Scope
We discuss your study, endpoints, and timelines under NDA
2
Design
We align on the bone-assessment plan and deliverables
1
Deliver
Central reading and analysis run across your sites as data arrives
2
Report
Analysis-ready datasets and reporting handed to your team
Start a conversation
Tell us about your study
Send us a note and our scientific team will get back to you to explore whether TBS® fits your programme.
- Pharmaceutical and biotech sponsors
- Contract research organisations
- Academic and investigator-led trials
- Medical-affairs and clinical-development teams
By submitting this form, you're not opting in to marketing communications. We'll use your details solely to contact you, nothing more. Read our privacy policy to see how we handle your information.
Talk to our clinical team and we'll point you to the right solution for your setting.
References (1)
1. Medimaps Group (2026) Internal data (data on file).